Call for Abstract

14th World Congress on Toxicology and Pharmacology, will be organized around the theme “Exploring Toxic Mysteries for Better Life”

Toxicology Congress 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Toxicology Congress 2018

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Clinical toxicology
  • Track 1-2Geriatric toxicology
  • Track 1-3Pediatric toxicology
  • Track 1-4Drug and chemical toxicology
  • Track 1-5Comprehensive toxicology
  • Track 1-6Organ toxicity
  • Track 1-7Neurotoxicology and teratology
  • Track 1-8Systemic toxicology
  • Track 1-9Predictive toxicology
  • Track 2-1Safety evaluation, risk and hazard assessment
  • Track 2-2Chemical research in toxicology
  • Track 2-3Regulatory toxicology
  • Track 2-4Computational toxicology
  • Track 2-5Toxicokinetics and Toxicodynamics
  • Track 3-1Animal testing methods
  • Track 3-2Alternative testing methods
  • Track 3-3Drug discovery, development and evaluation
  • Track 3-4In vitro toxicity testing
  • Track 3-5Pre-clinical toxicity testing
  • Track 4-1Genotoxic drugs
  • Track 4-2Genotoxicity testing
  • Track 4-3In vitro and in vivo testing
  • Track 4-4Pharmacogenetics & pharmacogenomics
  • Track 4-5Gentotoxicity and mutagenicity
  • Track 5-1Forensic samples for toxicology testing
  • Track 5-2Forensic toxicology applications
  • Track 5-3Challenges in forensic toxicology
  • Track 5-4Forensic toxicology today
  • Track 5-5Post-mortem Forensic Toxicology
  • Track 6-1Food safety and food allergies
  • Track 6-2Risk assessment of chemicals in food
  • Track 6-3Environmental and occupational health
  • Track 6-4Particle and fibre toxicology
  • Track 6-5Industrial and metallic toxicology
  • Track 6-6Plant toxicology
  • Track 6-7Aquatic Toxicology
  • Track 7-1Nanotoxicology
  • Track 7-2Innovations in applied toxicology and toxicological sciences
  • Track 7-3Emerging in-vitro models for the toxicity studies
  • Track 7-4Developmental and reproductive toxicology
  • Track 7-5Application of toxicology in drug development
  • Track 8-1Toxicologic pathology
  • Track 8-2In Vitro and In Vivo mechanisms
  • Track 8-3Xenobiotic Risk Characterization
  • Track 9-1Drugs of abuse
  • Track 9-2Unintentional and intentional overdoses
  • Track 9-3Evaluation of chemically induced diseases
  • Track 9-4Pre-Clinical toxicology studies
  • Track 10-1In vitro toxicity testing
  • Track 10-2Toxicity testing in preclinical development
  • Track 10-3Toxicity evaluation
  • Track 10-4Toxicological screening methods
  • Track 10-5Experimental toxicology
  • Track 10-6Human toxicology
  • Track 11-1Clinical pharmacology
  • Track 11-2Biochemical pharmacology
  • Track 11-3Neuropharmacology
  • Track 11-4Psychopharmacology
  • Track 11-5Respiratory pharmacology
  • Track 11-6Pediatric pharmacology
  • Track 11-7Geriatric pharmacology
  • Track 12-1Molecular and cellular pharmacology
  • Track 12-2Nanomedicine in pharmacology
  • Track 12-3Pharmacological testing
  • Track 12-4Behavioral pharmacology
  • Track 12-5Clinical application of systems pharmacology models
  • Track 13-1In vitro and In vivo models
  • Track 13-2Randomized controlled clinical trials
  • Track 13-3Pharmacokinetics
  • Track 13-4Pharmacologic stress testing
  • Track 13-5Drug reaction testing
  • Track 14-1Heart diseases and failure
  • Track 14-2Cardiovascular pharmacotherapies, cardiac procedures and surgeries
  • Track 14-3Risk factors for cardiovascular diseases
  • Track 14-4Interventional cardiology
  • Track 14-5Nuclear cardiology and echocardiography
  • Track 14-6Cerebrovascular heart diseases
  • Track 14-7Diseases associated with cardiovascular diseases
  • Track 14-8Heart diseases in different rationale
  • Track 15-1Pharmacodynamics and pharmacokinetics
  • Track 15-2Ethical and legal issues
  • Track 15-3Drug screening and discovery
  • Track 15-4Drug-drug interactions
  • Track 15-5Pharmacovigilance